Biogen Idec Inc (BIIB): Today's Featured Drugs Winner

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

Biogen Idec ( BIIB) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 0.5%. By the end of trading, Biogen Idec rose $3.31 (2.4%) to $141.24 on heavy volume. Throughout the day, 2.3 million shares of Biogen Idec exchanged hands as compared to its average daily volume of one million shares. The stock ranged in a price between $137.60-$142 after having opened the day at $137.60 as compared to the previous trading day's close of $137.93. Other companies within the Drugs industry that increased today were: Prana Biotechnology ( PRAN), up 16.9%, Zalicus ( ZLCS), up 15.6%, DARA Biosciences ( DARA), up 15%, and Delcath Systems ( DCTH), up 11.5%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $32.25 billion and is part of the health care sector. The company has a P/E ratio of 23.7, above the S&P 500 P/E ratio of 17.7. Shares are up 23.9% year to date as of the close of trading on Thursday. Currently there are 12 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and eight rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front, Dynavax Technologies Corporation ( DVAX), down 47.3%, Senesco Technologies ( SNT), down 15.8%, Tranzyme ( TZYM), down 15.6%, and MediciNova ( MNOV), down 10.1%, were all laggards within the drugs industry with AstraZeneca ( AZN) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

FREE for a limited time only: Get TheStreet Ratings #1 Stock Report NOW!.

null

More from Markets

Why Carvana - the Amazon of Cars - Isn't Worried About Trade Tariffs

Why Carvana - the Amazon of Cars - Isn't Worried About Trade Tariffs

Nektar is the One S&P 500 Company Without a Woman Director

Nektar is the One S&P 500 Company Without a Woman Director

Industrial Giants Take Down Dow, but Await Cooler Heads on Trade

Industrial Giants Take Down Dow, but Await Cooler Heads on Trade

Dow Tumbles 300 Points as Trump Ratchets Up China Trade Fight

Dow Tumbles 300 Points as Trump Ratchets Up China Trade Fight

Netflix Shares Hit All-Time High as Market Flounders

Netflix Shares Hit All-Time High as Market Flounders